 For all practical purposes, Sierra Oncology today is a single product company, solely focused on its most advanced product, momelotinib, which is targeted at Myelofibrosis. There will likely be easier times ahead, which will allow investors to take calls on the companys stock with far greater confidence, possibly after SRRAs ongoing Phase 3 trial results. 